Method for the production of bacterial toxins
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsMilan Blake, John Bogdan, Javier Nazario-Larrieu
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for the enhanced production of bacterial toxins in large-scale cultures. Specifically, methods and compositions for reducing bacterial toxin expression inhibitors are providing including, but not limited to, addition of toxin expression inhibitor binding compounds, culture media having reduced concentrations of toxin inhibitor metabolic precursors and genetically modified toxogenic bacteria lacking enzymes required to metabolize the toxin inhibitor metabolic precursors.
Claims8
A B. pertussis cysteine desulfinase knockout mutant having ATCC number ______.
A method of producing PT comprising growing a B. pertussis cysteine desulfinase knockout mutant in a B. pertussis culture medium, and isolating the PT from the culture medium.
A method for the enhanced production of PT, comprising cultivating B. pertussis cysteine desulfinase knockout mutant, whereby an enhanced amount of PT produced is produced compared to when a non-cysteine desulfinase knockout mutant is employed.
A peptide comprising the amino acid sequence GGGDGSFSGFGDGSFSGFG-OH (SEQ. ID. NO. 5).
A method of isolating a bacterial toxin from a mixture comprising:
- preparing a peptide affinity column wherein said peptide has the amino acid sequence comprising GGGDGSFSGFGDGSFSGFG-OH (SEQ. ID. NO. 5);
- adding said mixture containing said bacterial toxin to said peptide affinity column wherein said bacterial toxin binds to said peptide;
- releasing said bound bacterial toxin from said peptide;
- and
- collecting said isolated bacterial toxin.
Dependencies are inferred from the claim text.